From the identification of this pathogenetic mechanism in 2005 by Yokoyama et al. [43], ten years passed to the development of the first menin inhibitors, MI-463 and MI-503, developed by Borkin and colleagues in 2015 and successfully tested in AML mouse models harboring MLL rearrangements, granting a survival benefit without impairing normal hemopoiesis [44]. Here, KMT2A is linked to acute myeloid leukemia.